Beyond Air, Inc. Announces CEO Transition: Robert Goodman Appointed Chief Executive Officer

Key Points from the Report

• CEO Change: Steve Lisi, the long-time CEO of Beyond Air, Inc., has resigned and stepped down from the Board of Directors, effective March 27, 2026. Robert Goodman, previously Chief Commercial Officer and Director, has been appointed as the new CEO, effective immediately.
• Leadership Rationale: The Board believes Goodman’s commercial and operational expertise will accelerate market adoption and scale the company’s commercial growth, especially for its flagship product, LungFit PH.
• Product Success: Under Lisi’s leadership, Beyond Air successfully developed and launched LungFit PH, a medical device for treating neonatal hypoxic respiratory failure, receiving both FDA approval and CE Mark.
• Goodman’s Credentials: Goodman is a seasoned healthcare executive with leadership experience at BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer. He is also a retired U.S. Army officer and board member at Fourth Frontier, a wearable health tech company.
• Seamless Transition: The company expects no disruption to operations, customer relationships, or strategic priorities as a result of the leadership change.
• Forward-Looking Statements: The company is focused on expanding LungFit PH’s market adoption in the U.S. and internationally, and scaling commercial growth. However, risks remain, including execution of commercial strategy, leadership transition management, and financing.

Details Important for Shareholders

• Leadership Change and Strategic Impact: Leadership transitions at the CEO level are typically viewed as significant and potentially price-sensitive events. Goodman’s appointment signals a shift toward more aggressive commercialization, particularly for LungFit PH. Investors should monitor his execution of the new strategy, given his track record in rapid business transformation and global expansion.
• Product Traction and Market Opportunity: LungFit PH has regulatory approvals and is positioned for wider adoption. The company’s commitment to expanding in both U.S. and international markets may materially impact future revenue streams.
• Operational Stability: The company assures investors that the transition will be seamless, with no expected disruption to ongoing business activities.
• Potential Risks: Forward-looking statements highlight risks related to execution, adoption, customer relationships, leadership transition, and financing. These factors could affect share value if not managed properly.
• Goodman’s Experience: Goodman’s history of successful exits and scaling businesses could be seen as positive by investors, suggesting potential for increased shareholder value if he delivers on growth targets.
• Share Price Sensitivity: CEO transitions, especially those accompanied by promises of accelerated commercial growth and global expansion, are often viewed as material information by investors and can move the share price.

In-Depth Article for Investors

Beyond Air, Inc. (NASDAQ: XAIR) has announced a major leadership change that could significantly impact its strategic direction and share price. On March 26, 2026, the company revealed that Steve Lisi, who has served as CEO for nine years, is stepping down from both his executive role and the Board of Directors to pursue other opportunities.

Robert Goodman, previously Chief Commercial Officer and Director, will immediately assume the role of Chief Executive Officer. The Board, led by Chairman Robert F. Carey, cited Goodman’s extensive commercial and operational expertise, especially in U.S. and international markets, as key to accelerating the adoption of LungFit PH and scaling the company’s commercial operations.

Under Steve Lisi’s guidance, Beyond Air brought LungFit PH—a revolutionary technology for treating neonatal hypoxic respiratory failure—to market. This product achieved both FDA approval and CE Mark, establishing a foundation for further expansion. Lisi’s departure marks the end of an era characterized by product development and regulatory milestones. The Board expressed gratitude for his visionary leadership, noting his critical contributions to the company’s trajectory.

Goodman, who joined the Board in June 2025 and became Chief Commercial Officer in November 2025, has already led a rapid transformation of Beyond Air’s business strategy. His prior experience includes senior roles at BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer, spanning public companies, private equity–backed businesses, and early-stage ventures. He also serves on the board of Fourth Frontier, a wearable health tech company, and brings a disciplined, strategic mindset from his military career as a retired U.S. Army officer.

Goodman stated his commitment to sharpening commercial execution, strengthening customer partnerships, and scaling the company for long-term growth and enhanced shareholder value. His track record of guiding companies through rapid growth, global expansion, and successful exits may be viewed favorably by investors seeking accelerated performance.

The company emphasizes a seamless transition with no anticipated disruption to operations, customer relationships, or strategic priorities. Beyond Air remains focused on harnessing endogenous and exogenous nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors. The leadership change is positioned as a catalyst for accelerating commercial growth, particularly for LungFit PH in the U.S. and abroad.

Forward-looking statements in the press release acknowledge risks inherent to the leadership transition, commercial execution, and market expansion. These risks, if not managed effectively, could materially affect share value. Investors should closely monitor Goodman’s ability to deliver on promises of scalable and sustainable growth.

Contact Information

For investor relations inquiries, contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Email: [email protected]
Phone: (212) 915-2577

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements reflect management’s current expectations and are subject to risks and uncertainties. Investors should perform their own due diligence and consult with financial advisors before making investment decisions related to Beyond Air, Inc. The information herein is based on the company’s official press release and may be subject to change.

View Beyond Air, Inc. Historical chart here